MRNA News and Press, Moderna Inc. From 06/19/24

2024-06-19 19:47:42 ET Summary Coatue Management's 13F portfolio value increased from $23.84B to $25.50B this quarter, with around 75 individual stock positions. New stakes include Qualcomm, Broadcom, Dell Technologies, and Constellation Energy, while stakes in Apple, Walt Disney,...

2024-06-18 15:03:18 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax Read the full article on Seeking Alpha...

2024-06-18 03:42:39 ET Summary Moderna's RSV vaccine has been approved by the FDA, but it faces competition from GSK and PFE's offerings. A June 26 meeting of the Advisory Committee on Immunization Practices is a near-term catalyst. MRNA is hoping for parity with GSK/PFE when it c...

2024-06-16 09:45:00 ET Moderna (NASDAQ: MRNA) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have lagged over the past three years -- its COVID-19 vaccine sales dr...

2024-06-14 15:21:25 ET Moderna ( MRNA ) shares traded in the red on Friday, making it the seventh straight day of losses. The stock is down 4.03% at $139.38.... Read the full article on Seeking Alpha For further details see: Moderna stock traded in the red for seven stra...

2024-06-13 18:34:04 ET More on BioNTech, Moderna, etc. BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcar...

2024-06-13 07:26:13 ET More on Moderna Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) Jefferies 2024 Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcr...

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age a...

2024-06-12 09:00:09 ET Hartaj Singh from Oppenheimer issued a price target of $179.00 for MRNA on 2024-06-12 07:41:00. The adjusted price target was set to $179.00. At the time of the announcement, MRNA was trading at $148.39. The overall price target consensus is at $16...

2024-06-10 15:47:08 ET Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024, 01:20 PM ET Company Participants Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Presentation ...